SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update
SCIENTURE (NASDAQ: SCNX) reported Q3 2025 results and a business update on November 13, 2025. The company launched Arbli™, the first FDA-approved ready-to-use liquid formulation of losartan, and began commercial sales.
Q3 2025 vs Q3 2024: net revenue rose from ~$65K to $590K, and gross profit increased from ~$4K to $575K. Arbli was added to national payor formularies covering >100 million lives and secured GPO agreements reaching >2,500 institutions (~20% of U.S. institutional market). Post-quarter, the company reduced outstanding debt and reported cash of >$8 million as of November 13, 2025. Management plans a commercial launch of REZENOPY® in Q1 2026.
SCIENTURE (NASDAQ: SCNX) ha riportato i risultati del terzo trimestre 2025 e un aggiornamento aziendale il 13 novembre 2025. L'azienda ha lanciato Arbli™, la prima formulazione liquida pronta all'uso di losartan, approvata dalla FDA, e ha avviato le vendite commerciali.
Q3 2025 vs Q3 2024: ricavi netti sono aumentati da ~$65K a $590K, e margine di profitto lordo è salito da ~$4K a $575K. Arbli è stato inserito nei formulari payor nazionali che coprono > 100 milioni di vite e ha assicurato accordi GPO che raggiungono >2.500 istituzioni (~20% del mercato istituzionale statunitense). Dopo il trimestre, l'azienda ha ridotto il debito pendente e ha riportato una cassa di >$8 milioni al 13 novembre 2025. La direzione prevede un lancio commerciale di REZENOPY® nel Q1 2026.
SCIENTURE (NASDAQ: SCNX) informó resultados del 3er trimestre de 2025 y una actualización comercial el 13 de noviembre de 2025. La empresa lanzó Arbli™, la primera formulación líquida lista para usar de losartán, aprobada por la FDA, y comenzó ventas comerciales.
3T 2025 vs 3T 2024: ingresos netos aumentaron de ~$65K a $590K, y beneficio bruto pasó de ~$4K a $575K. Arbli se agregó a los formularios de pagadores nacionales que cubren > 100 millones de vidas y se aseguraron acuerdos GPO que alcanzan >2,500 instituciones (~20% del mercado institucional de EE. UU.). Después del trimestre, la empresa redujo la deuda pendiente y reportó una caja de > $8 millones al 13 de noviembre de 2025. La dirección planea un lanzamiento comercial de REZENOPY® en el Q1 2026.
SCIENTURE (NASDAQ: SCNX)는 2025년 11월 13일 3분기 2025 실적 및 사업 업데이트를 발표했다. 회사는 FDA 승인된 losartan의 첫 번째 즉시 사용 가능한 액상 제형인 Arbli™를 출시했고 상업 판매를 시작했다.
3Q 2025 대 3Q 2024: 순매출은 ~$65K에서 $590K로 증가했고, 총이익은 ~$4K에서 $575K로 증가했다. Arbli는 전국 규모의 payer formularies가 커버하는 1억 명의 생명을 포함했고, >2,500개 기관에 도달하는 GPO 계약이 확정되었다(미국 기관 시장의 약 20%). 분기 이후 회사는 미지급 부채를 줄였고 2025년 11월 13일 기준 현금은 $8백만으로 보고되었다. 경영진은 2026년 1분기에 REZENOPY®의 상용 출시를 계획하고 있다.
SCIENTURE (NASDAQ: SCNX) a publié les résultats du T3 2025 et une mise à jour commerciale le 13 novembre 2025. L'entreprise a lancé Arbli™, la première formulation liquide prête à l'emploi de losartan approuvée par la FDA, et a commencé les ventes commerciales.
Q3 2025 vs Q3 2024: chiffre d'affaires net est passé de ~65K$ à 590K$, et marge brute est passée de ~4K$ à 575K$. Arbli a été ajouté aux formulaires nationaux des payeurs couvrant > 100 millions de vies et des accords GPO ont été obtenus atteignant >2 500 institutions (~20% du marché institutionnel américain). Après le trimestre, l'entreprise a réduit sa dette et a annoncé une trésorerie de > 8 millions de dollars au 13 novembre 2025. La direction prévoit un lancement commercial de REZENOPY® au 1er trimestre 2026.
SCIENTURE (NASDAQ: SCNX) meldete die Ergebnisse des dritten Quartals 2025 und ein Unternehmensupdate am 13. November 2025. Das Unternehmen brachte Arbli™ auf den Markt, die erste FDA-gewährte gebrauchsfertige flüssige Formulierung von Losartan, und begann den kommerziellen Verkauf.
Q3 2025 vs Q3 2024: Nettoumsatz stieg von ca. $65K auf $590K, und Bruttogewinn wuchs von ca. $4K auf $575K. Arbli wurde in nationale Payor-Formulare aufgenommen, die > 100 Millionen Leben abdecken, und es wurden GPO-Vereinbarungen erzielt, die >2.500 Institutionen erreichen (~20% des US-Institutionalmarkts). Nach dem Quartal reduzierte das Unternehmen die ausstehende Verschuldung und meldete am 13. November 2025 einen Bargeldbestand von > $8 Millionen. Das Management plant einen kommerziellen Start von REZENOPY® im Q1 2026.
SCIENTURE (NASDAQ: SCNX) أبلغت عن نتائج الربع الثالث لعام 2025 وتحديثًا تجاريًا في 13 نوفمبر 2025. أطلقت الشركة Arbli™، أول صيغة سائلة جاهزة للاستخدام من Losartan المعتمدة من FDA، وبدأت المبيعات التجارية.
الربع الثالث 2025 مقابل الربع الثالث 2024: الإيرادات الصافية ارتفعت من حوالي 65 ألف دولار إلى $590 ألف، و< b>الربح الإجمالي ارتفع من حوالي 4 آلاف دولار إلى $575 ألف. أُضيف Arbli إلى القوائم الوطنية لمقدمي الدفع التي تغطي > 100 مليون حياة وتم تأمين اتفاقيات GPO تصل إلى >2,500 مؤسسة (~20% من السوق المؤسسي الأمريكي). بعد الربع، قلّصت الشركة الدين المستحق وذكرت بأن النقد لديها كان $8 مليون حتى 13 نوفمبر 2025. وتخطط الإدارة لإطلاق تجاري لـ REZENOPY® في الربع الأول من 2026.
- Net revenue increased from ~$65K to $590K in Q3 2025
- Gross profit rose from ~$4K to $575K in Q3 2025
- Arbli is FDA-approved and launched commercially
- Payor formulary coverage expanded to >100 million covered lives
- GPO agreements reach >2,500 institutions (~20% U.S. institutional market)
- Cash position strengthened to >$8M as of November 13, 2025 after debt reduction
- Q3 2025 net revenue remains modest at $590K
- Commercial portfolio currently centered on a single FDA-approved product, Arbli
Insights
Launch traction and formulary wins materially expand commercial reach; retail and institutional uptake will determine sustainability.
Sales initiation of Arbli™ produced a step-change in top-line performance, with net revenue rising to
Near-term risk hinges on real-world demand, refill and adherence patterns, and the speed of uptake within covered populations; formulary placement alone does not guarantee sustained prescribing. Watch product-level sell-through, inventory at major wholesalers, and sequential monthly revenue for the next
Financial metrics show positive early commercial economics and materially improved liquidity after debt reduction.
Quarterly net revenue of
Key near-term items to monitor include monthly operating cash burn, SG&A related to the Arbli™ launch, and inventory purchases tied to institutional contracts; expect clearer financial direction when the company reports sequential monthly revenue trends and the planned commercial launch of REZENOPY® in
Reports Significant Revenue Growth to
Launched Sales of Arbli™, the First FDA-Approved Ready-To-Use Liquid Formulation of Losartan for Hypertension
COMMACK, NY, Nov. 13, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a business update and reported financial results for the third quarter ended September 30, 2025.
Third Quarter 2025 Highlights Compared to Third Quarter 2024:
- Launched sales of Arbli™ (losartan potassium).
- Net revenue increased from approximately
$65 thousand to$590 thousand . - Gross profit increased from approximately
$4 thousand to$575 thousand .
“Q3 was a transformational quarter for Scienture as we commenced sales of Arbli™,” commented Narasimhan Mani, President and Co-CEO of Scienture. “We delivered strong results this quarter, with significant increases in net revenues and gross profit as we entered full commercial scale-up of our first FDA-approved product, Arbli™. In the past month, Arbli™ was added to key national payor formularies, expanding access to over 100 million covered lives, and we secured GPO agreements reaching more than 2,500 healthcare institutions, representing potential penetration into roughly
“Backed by a strong commercial infrastructure and the successful launch of Arbli™, Scienture is preparing to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment, in Q1 2026,” stated Shankar Hariharan, Executive Chairman and co-CEO of Scienture. “REZENOPY® is the most potent naloxone HCl product currently available, leveraging a proven active ingredient and delivery method while offering increased effectiveness against today’s more powerful opioids. Additionally, our development pipeline remains strong, and we continue to evaluate additional opportunities to add accretive products to our commercial portfolio. Delivering sustained shareholder value remains the Company’s core priority.”
About Arbli™
Arbli™ is a novel proprietary formulation of losartan, a widely prescribed angiotensin receptor blocker (ARB) for hypertension. It is the first and only liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf life at room temperature storage. Arbli™ is FDA-approved for the treatment of hypertension in patients greater than six years old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic nephropathy in certain patients with type 2 diabetes. By offering a safe, effective, and convenient liquid alternative, Arbli™ provides a tailored solution for patients who require or prefer a liquid formulation. As an FDA-approved product, Arbli™ provides consistent quality and dosing accuracy, addressing the risks and inconsistencies often associated with extemporaneously compounded losartan prescriptions. Arbli™ has two issued patents from the USPTO, which are also listed in the FDA Orangebook.
Arbli™ is the first and only oral liquid formulation of losartan approved by the U.S. FDA. Arbli™ comes in a 165 mL bottle as a peppermint flavored suspension that does not require refrigeration, and has been approved for a shelf life of 24 months from the date of manufacture when stored at room temperature.
INDICATION
Arbli™ is an angiotensin II receptor blocker (ARB) indicated for:
- Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
- Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy.
- Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.
IMPORTANT SAFETY INFORMATION
- Do not take Arbli™ when pregnant. When pregnancy is detected, discontinue Arbli™ as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. Arbli™ can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.
- Do not co-administer Arbli™ with aliskiren in patients with diabetes. Avoid use of aliskiren with Arbli™ in patients with renal impairment (GFR <60 mL/min).
- Do not administer Arbli™ in patients with severe hepatic impairment. Arbli™ has not been studied in patients with severe hepatic impairment.
- The most common adverse reactions are (incidence ≥
2% and greater than placebo): dizziness, upper respiratory infection, nasal congestion, and back pain.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also contact Scienture at 1-833-754-4917.
Please see the full Prescribing Information for complete product information. For more information, talk to your healthcare provider.
About Hypertension
Hypertension (high blood pressure) is a cardiovascular condition, when the pressure in the blood vessels is too high (140/90 mmHg or higher). According to the CDC, hypertension, or high blood pressure, affects nearly half of adults in the United States, or 119.9 million people. Hypertension is defined as a systolic blood pressure of 140 mmHg or higher, and diastolic blood pressure of 90 mmHg or higher. Hypertension is a risk factor for stroke and heart disease, which are leading causes of death in the U.S. Factors that increase the risk of having high blood pressure include: older age, genetics, being overweight or obese, not being physically active, high-salt diet and drinking too much alcohol. Hypertension is clinically diagnosed if, when blood pressure is measured on two different days, the systolic blood pressure readings on both days is ≥140 mmHg and/or the diastolic blood pressure readings on both days is ≥ 90 mmHg.
About Scienture Holdings, Inc.
SCIENTURE HOLDINGS, INC. (NASDAQ: “SCNX”), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit: www.scientureholdings.com and www.scienture.com.
Cautionary Statements Regarding Forward-Looking Statements
This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch, the success those products may have in the marketplace, our strategies related to those products, and our future financial condition and results from operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K and subsequent reports filed with the SEC.
Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.
Contact:
SCIENTURE HOLDINGS, INC.
20 Austin Blvd
Commack, NY 11725
Phone: (866) 468-6535
Email: IR@Scienture.com
(Tables follow)
Scienture Holdings, Inc. formerly TRxADE HEALTH, INC.
Condensed Consolidated Balance Sheets
As of September 30, 2025 and December 31, 2024
(Unaudited)
| September 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash | $ | 355,692 | $ | 308,096 | ||||
| Accounts receivable, net | 590,050 | 11,106 | ||||||
| Inventory | 234,521 | - | ||||||
| Prepaid expenses | 240,811 | 4,560 | ||||||
| Notes receivable - related party | - | 1,300,000 | ||||||
| Other receivables | - | 4,138,770 | ||||||
| Deferred offering costs | - | 534,800 | ||||||
| Current assets of discontinued operations | - | 8,145 | ||||||
| Total current assets | 1,421,074 | 6,305,477 | ||||||
| Property, plant and equipment, net | 16,000 | 17,500 | ||||||
| Deposits | - | 22,039 | ||||||
| Notes receivable | 5,000,000 | - | ||||||
| Interest receivable | 62,500 | - | ||||||
| Intangible assets, net | 76,400,000 | 76,400,000 | ||||||
| Goodwill | 21,372,960 | 21,372,960 | ||||||
| Operating lease right-of-use assets | 23,360 | 201,433 | ||||||
| Deferred tax asset | 534,396 | 534,396 | ||||||
| Total assets | $ | 104,830,290 | $ | 104,853,805 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 3,672,860 | $ | 2,898,683 | ||||
| Accrued liabilities | 984,825 | 1,313,731 | ||||||
| Other current liabilities | - | 5,441 | ||||||
| Loan payable, related party | 531,000 | 415,000 | ||||||
| Convertible note, net of debt discount - current portion | 2,000,000 | 2,285,423 | ||||||
| Operating lease liability - current | 24,137 | 63,334 | ||||||
| Warrant liability | 138,624 | 919,935 | ||||||
| Current liabilities of discontinued operations | - | 5,346 | ||||||
| Total current liabilities | 7,351,446 | 7,906,893 | ||||||
| Convertible notes, net of debt discount | - | 612,275 | ||||||
| Derivative liability | - | 2,296,834 | ||||||
| Operating lease liability - net of current portion | - | 156,469 | ||||||
| Development agreement liability | 1,285,000 | 1,285,000 | ||||||
| Deferred tax liability | 13,524,213 | 13,524,213 | ||||||
| Total liabilities | 22,160,659 | 25,781,684 | ||||||
| Commitments and contingencies (Note 15) | ||||||||
| Stockholders’ equity (deficit): | ||||||||
| Series A preferred stock, | - | - | ||||||
| Series B preferred stock, | - | - | ||||||
| Series C preferred stock, | - | - | ||||||
| Series X preferred stock, | - | - | ||||||
| Common stock, | 231 | 87 | ||||||
| Additional paid-in capital | 135,100,304 | 118,111,007 | ||||||
| Accumulated deficit | (52,430,904 | ) | (39,038,973 | ) | ||||
| Total stockholders’ equity | 82,669,631 | 79,072,121 | ||||||
| Total liabilities and stockholders’ equity | $ | 104,830,290 | $ | 104,853,805 | ||||
Scienture Holdings, Inc. formerly TRxADE HEALTH, INC.
Condensed Consolidated Statements Of Operations
For the Three and Nine Months Ended September 30, 2025 and 2024
(Unaudited)
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenues | $ | 590,050 | $ | 64,861 | $ | 600,308 | $ | 83,560 | ||||||||
| Cost of goods sold | 15,429 | 60,978 | 25,014 | 80,380 | ||||||||||||
| Gross profit | 574,621 | 3,883 | 575,294 | 3,180 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Wage and salary expense | 251,747 | 708,977 | 1,721,554 | 1,243,621 | ||||||||||||
| Professional fees | 1,320,845 | 593,364 | 1,943,458 | 1,282,053 | ||||||||||||
| Accounting and legal expense | 1,018,737 | 619,227 | 1,871,245 | 1,129,982 | ||||||||||||
| Technology expense | 9,756 | 157,474 | 92,784 | 295,763 | ||||||||||||
| General and administrative | 2,165,398 | 168,649 | 6,449,110 | 5,284,231 | ||||||||||||
| Research and development | 169,344 | 1,253,983 | 1,587,572 | 1,253,983 | ||||||||||||
| Total operating expenses | 4,935,827 | 3,501,674 | 13,665,723 | 10,489,633 | ||||||||||||
| Operating loss | (4,361,206 | ) | (3,497,791 | ) | (13,090,429 | ) | (10,486,453 | ) | ||||||||
| Non-operating income (expense): | ||||||||||||||||
| Change in fair value of warrant liability | 59,203 | 502,178 | 781,311 | (392,843 | ) | |||||||||||
| Change in fair value of derivative liability | 2,356,428 | - | 2,296,834 | - | ||||||||||||
| Loss on conversion of note payable | 43,200 | - | (53,446 | ) | - | |||||||||||
| Loss on disposition of subsidiaries | 97,324 | - | (288,204 | ) | - | |||||||||||
| Interest income | 1,120 | 29,445 | 89,710 | 133,397 | ||||||||||||
| Loss on disposal of asset | - | - | - | (374,968 | ) | |||||||||||
| Interest expense | (1,803,430 | ) | (217,433 | ) | (3,127,707 | ) | (320,897 | ) | ||||||||
| Total non-operating expense | 753,845 | 314,190 | (301,502 | ) | (955,311 | ) | ||||||||||
| Net loss from continuing operations | (3,607,361 | ) | (3,183,601 | ) | (13,391,931 | ) | (11,441,764 | ) | ||||||||
| Benefit / (provision) for income taxes | - | - | - | - | ||||||||||||
| Net loss from continuing operations, net of tax | (3,607,361 | ) | (3,183,601 | ) | (13,391,931 | ) | (11,441,764 | ) | ||||||||
| Net income from discontinued operations, net of tax | - | - | - | 27,670,294 | ||||||||||||
| Net (loss) income | $ | (3,607,361 | ) | $ | (3,183,601 | ) | $ | (13,391,931 | ) | $ | 16,228,530 | |||||
| Net loss per common share from continuing operations | ||||||||||||||||
| Basic | $ | (0.19 | ) | $ | (1.34 | ) | $ | (0.94 | ) | $ | (7.10 | ) | ||||
| Diluted | $ | (0.19 | ) | $ | (1.34 | ) | $ | (0.94 | ) | $ | (7.10 | ) | ||||
| Net (loss) income per common share from discontinued operations | ||||||||||||||||
| Basic | $ | - | $ | - | $ | - | $ | 17.17 | ||||||||
| Diluted | $ | - | $ | - | $ | - | $ | 14.64 | ||||||||
| Net (loss) income per common share | ||||||||||||||||
| Basic | $ | (0.19 | ) | $ | (1.34 | ) | $ | (0.94 | ) | $ | 10.07 | |||||
| Diluted | $ | (0.19 | ) | $ | (1.34 | ) | $ | (0.94 | ) | $ | 8.59 | |||||
| Weighted average common shares outstanding | ||||||||||||||||
| Basic | 18,957,653 | 2,373,848 | 14,269,905 | 1,611,221 | ||||||||||||
| Diluted | 18,957,653 | 2,373,848 | 14,269,905 | 1,889,504 | ||||||||||||
FAQ
What did SCIENTURE (SCNX) report for Q3 2025 revenue and gross profit?
When did SCIENTURE launch Arbli and what is it?
How much patient coverage did Arbli gain from payor formularies?
What institutional reach did SCIENTURE secure for Arbli via GPO agreements?
What is SCIENTURE's cash position and balance sheet update as of November 13, 2025?
When is SCIENTURE planning the commercial launch of REZENOPY (SCNX)?
